Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback